860 related articles for article (PubMed ID: 33493450)
21. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
[TBL] [Abstract][Full Text] [Related]
22. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.
Bozzi G; Mangioni D; Minoia F; Aliberti S; Grasselli G; Barbetta L; Castelli V; Palomba E; Alagna L; Lombardi A; Ungaro R; Agostoni C; Baldini M; Blasi F; Cesari M; Costantino G; Fracanzani AL; Montano N; Monzani V; Pesenti A; Peyvandi F; Sottocorno M; Muscatello A; Filocamo G; Gori A; Bandera A
J Allergy Clin Immunol; 2021 Feb; 147(2):561-566.e4. PubMed ID: 33220354
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial.
Audemard-Verger A; Le Gouge A; Pestre V; Courjon J; Langlois V; Vareil MO; Devaux M; Bienvenu B; Leroy V; Goulabchand R; Colombain L; Bigot A; Guimard T; Douadi Y; Urbanski G; Faucher JF; Maulin L; Lioger B; Talarmin JP; Groh M; Emmerich J; Deriaz S; Ferreira-Maldent N; Cook AR; Lengellé C; Bourgoin H; Mekinian A; Aouba A; Maillot F; Caille A
PLoS One; 2022; 17(8):e0269065. PubMed ID: 35925914
[TBL] [Abstract][Full Text] [Related]
24. Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group.
Hermine O; Mariette X; Porcher R; Djossou F; Nguyen Y; Arlet JB; Savale L; Diehl JL; Georgin-Lavialle S; Cadranel J; Pialoux G; Lacombe K; Mekinian A; Gros H; Lescure X; Ghosn J; Coupez E; Grapin K; Rapp C; Michel M; Lecapitaine AL; Michot JM; Costedoat-Chalumeau N; Nguyen LBL; Semerano L; Raffi F; Aguillar C; Rouzaud C; Gottenberg JE; Hansmann Y; Bienvenu B; London J; Fantchou FS; Ackermann F; Gros A; Morel A; Gambier N; Sène D; Mégarbane B; Azoulay E; Bureau S; Dougados M; Emmerich J; Fartoukh M; Guidet B; Humbert M; Mahevas M; Pène F; Schlemmer F; Pourcher-Martinez V; Tibi A; Baron G; Perrodeau E; Baron S; Steg G; Yazdapanah Y; Simon T; Resche-Rigon M; Tharaux PL; Ravaud P
EClinicalMedicine; 2022 Apr; 46():101362. PubMed ID: 35350097
[TBL] [Abstract][Full Text] [Related]
25. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group.
Hermine O; Mariette X; Porcher R; Resche-Rigon M; Tharaux PL; Ravaud P;
Eur Respir J; 2022 Aug; 60(2):. PubMed ID: 35115337
[TBL] [Abstract][Full Text] [Related]
26. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
Butler CC; Yu LM; Dorward J; Gbinigie O; Hayward G; Saville BR; Van Hecke O; Berry N; Detry MA; Saunders C; Fitzgerald M; Harris V; Djukanovic R; Gadola S; Kirkpatrick J; de Lusignan S; Ogburn E; Evans PH; Thomas NPB; Patel MG; Hobbs FDR;
Lancet Respir Med; 2021 Sep; 9(9):1010-1020. PubMed ID: 34329624
[TBL] [Abstract][Full Text] [Related]
27. Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial.
Dushianthan A; Clark H; Madsen J; Mogg R; Matthews L; Berry L; de la Serna JB; Batchelor J; Brealey D; Hussell T; Porter J; Djukanovic R; Feelisch M; Postle A; Grocott MPW
Trials; 2020 Dec; 21(1):1014. PubMed ID: 33302976
[TBL] [Abstract][Full Text] [Related]
28. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
[TBL] [Abstract][Full Text] [Related]
29. Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial.
Annane D; Pittock SJ; Kulkarni HS; Pickering BW; Khoshnevis MR; Siegel JL; Powell CA; Castro P; Fujii T; Dunn D; Smith K; Mitter S; Kazani S; Kulasekararaj A
Lancet Respir Med; 2023 Dec; 11(12):1051-1063. PubMed ID: 36958364
[TBL] [Abstract][Full Text] [Related]
30. Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial.
Lacombe K; Hueso T; Porcher R; Mekinian A; Chiarabini T; Georgin-Lavialle S; Ader F; Saison J; Martin-Blondel G; De Castro N; Bonnet F; Cazanave C; Francois A; Morel P; Hermine O; Pourcher V; Michel M; Lescure X; Soussi N; Brun P; Pommeret F; Sellier P; Rousset S; Piroth L; Michot JM; Baron G; de Lamballerie X; Mariette X; Tharaux PL; Resche-Rigon M; Ravaud P; Simon T; Tiberghien P
BMJ Med; 2023; 2(1):e000427. PubMed ID: 37920150
[TBL] [Abstract][Full Text] [Related]
31. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
32. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.
Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568
[TBL] [Abstract][Full Text] [Related]
33. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
Butler CC; Hobbs FDR; Gbinigie OA; Rahman NM; Hayward G; Richards DB; Dorward J; Lowe DM; Standing JF; Breuer J; Khoo S; Petrou S; Hood K; Nguyen-Van-Tam JS; Patel MG; Saville BR; Marion J; Ogburn E; Allen J; Rutter H; Francis N; Thomas NPB; Evans P; Dobson M; Madden TA; Holmes J; Harris V; Png ME; Lown M; van Hecke O; Detry MA; Saunders CT; Fitzgerald M; Berry NS; Mwandigha L; Galal U; Mort S; Jani BD; Hart ND; Ahmed H; Butler D; McKenna M; Chalk J; Lavallee L; Hadley E; Cureton L; Benysek M; Andersson M; Coates M; Barrett S; Bateman C; Davies JC; Raymundo-Wood I; Ustianowski A; Carson-Stevens A; Yu LM; Little P;
Lancet; 2023 Jan; 401(10373):281-293. PubMed ID: 36566761
[TBL] [Abstract][Full Text] [Related]
34. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
PRINCIPLE Trial Collaborative Group
Lancet; 2021 Mar; 397(10279):1063-1074. PubMed ID: 33676597
[TBL] [Abstract][Full Text] [Related]
35. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.
Lescure FX; Honda H; Fowler RA; Lazar JS; Shi G; Wung P; Patel N; Hagino O;
Lancet Respir Med; 2021 May; 9(5):522-532. PubMed ID: 33676590
[TBL] [Abstract][Full Text] [Related]
36. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
[TBL] [Abstract][Full Text] [Related]
37. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.
Ramakrishnan S; Nicolau DV; Langford B; Mahdi M; Jeffers H; Mwasuku C; Krassowska K; Fox R; Binnian I; Glover V; Bright S; Butler C; Cane JL; Halner A; Matthews PC; Donnelly LE; Simpson JL; Baker JR; Fadai NT; Peterson S; Bengtsson T; Barnes PJ; Russell REK; Bafadhel M
Lancet Respir Med; 2021 Jul; 9(7):763-772. PubMed ID: 33844996
[TBL] [Abstract][Full Text] [Related]
38. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial.
Aman J; Duijvelaar E; Botros L; Kianzad A; Schippers JR; Smeele PJ; Azhang S; Bartelink IH; Bayoumy AA; Bet PM; Boersma W; Bonta PI; Boomars KAT; Bos LDJ; van Bragt JJMH; Braunstahl GJ; Celant LR; Eger KAB; Geelhoed JJM; van Glabbeek YLE; Grotjohan HP; Hagens LA; Happe CM; Hazes BD; Heunks LMA; van den Heuvel M; Hoefsloot W; Hoek RJA; Hoekstra R; Hofstee HMA; Juffermans NP; Kemper EM; Kos R; Kunst PWA; Lammers A; van der Lee I; van der Lee EL; Maitland-van der Zee AH; Mau Asam PFM; Mieras A; Muller M; Neefjes ECW; Nossent EJ; Oswald LMA; Overbeek MJ; Pamplona CC; Paternotte N; Pronk N; de Raaf MA; van Raaij BFM; Reijrink M; Schultz MJ; Serpa Neto A; Slob EMA; Smeenk FWJM; Smit MR; Smits AJ; Stalenhoef JE; Tuinman PR; Vanhove ALEM; Wessels JN; van Wezenbeek JCC; Vonk Noordegraaf A; de Man FS; Bogaard HJ
Lancet Respir Med; 2021 Sep; 9(9):957-968. PubMed ID: 34147142
[TBL] [Abstract][Full Text] [Related]
39. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
;
Lancet; 2023 May; 401(10387):1499-1507. PubMed ID: 37060915
[TBL] [Abstract][Full Text] [Related]
40. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet; 2021 Feb; 397(10274):605-612. PubMed ID: 33545096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
